+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Liver Cancer Drugs Market by Type, Distribution channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4896742
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Liver Cancer Drugs Market grew from USD 866.70 million in 2023 to USD 987.60 million in 2024. It is expected to continue growing at a CAGR of 14.04%, reaching USD 2.17 billion by 2030.

The liver cancer drugs market encompasses a diverse array of pharmaceutical solutions aimed at diagnosing, treating, and managing liver cancer, which remains a significant global health challenge. This market is characterized primarily by drug types including chemotherapy, immunotherapy, targeted therapy, and antiviral drugs, each tailored to combat different aspects and symptoms of liver cancer. The necessity of these drugs stems from the increasing incidence of liver cancer globally, driven by risk factors such as hepatitis infections, rising alcohol consumption, and obesity, necessitating robust treatment options. Applications of these drugs extend from primary treatment to preoperative, palliative care, and combination therapies, serving end-users such as hospitals, cancer treatment centers, and research institutes. Key growth drivers include advancements in precision medicine, increasing R&D activities, and growing awareness about early diagnosis and innovative therapies. The current trends also highlight a surge in collaborations between biotech firms and pharmaceutical giants aiming to accelerate drug development pipelines. However, the market faces challenges such as high treatment costs, stringent regulatory approvals, and potential side effects that limit patient adoption. Additionally, regional disparities in healthcare infrastructure can hinder market penetration in developing regions. Opportunities lie in personalized medicine, leveraging AI and machine learning for drug development, and ongoing clinical trials that offer potential breakthroughs. Businesses can capitalize on these by investing in targeted therapies that boast higher efficacy and minimal side effects and by tapping into emerging markets with a scalable and affordable drug portfolio. However, firms must navigate IP constraints and adapt to evolving market regulations. Innovation can focus on integrating technology with healthcare, such as developing bioinformatics tools for predictive analytics and patient-centric drug models, which can redefine treatment paradigms and offer substantial market leverage. Overall, the liver cancer drugs market, although challenging, promises robust future growth driven by scientific advancements and global healthcare initiatives.

Understanding Market Dynamics in the Liver Cancer Drugs Market

The Liver Cancer Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of liver cancer
    • Increasing initiatives for the awareness regarding liver cancer
    • Rapid adoption of precision medicine and emergence of targeted therapies
  • Market Restraints
    • High cost for developing liver cancer drugs
  • Market Opportunities
    • Ongoing regulatory approvals for the liver cancer drugs
    • Growing R&D investments for the development of novel drugs
  • Market Challenges
    • Adverse side effects of liver cancer drugs

Exploring Porter’s Five Forces for the Liver Cancer Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Liver Cancer Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Liver Cancer Drugs Market

External macro-environmental factors deeply influence the performance of the Liver Cancer Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Liver Cancer Drugs Market

The Liver Cancer Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Liver Cancer Drugs Market

The Liver Cancer Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Liver Cancer Drugs Market

The Liver Cancer Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celsion Corporation, Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd, Lion TCR Pte. Ltd., Merck & Co., Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Immuno Therapy
    • Targeted Therapy
  • Distribution channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of liver cancer
5.1.1.2. Increasing initiatives for the awareness regarding liver cancer
5.1.1.3. Rapid adoption of precision medicine and emergence of targeted therapies
5.1.2. Restraints
5.1.2.1. High cost for developing liver cancer drugs
5.1.3. Opportunities
5.1.3.1. Ongoing regulatory approvals for the liver cancer drugs
5.1.3.2. Growing R&D investments for the development of novel drugs
5.1.4. Challenges
5.1.4.1. Adverse side effects of liver cancer drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Liver Cancer Drugs Market, by Type
6.1. Introduction
6.2. Immuno Therapy
6.3. Targeted Therapy
7. Liver Cancer Drugs Market, by Distribution channel
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy
8. Americas Liver Cancer Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Liver Cancer Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Liver Cancer Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. LIVER CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. LIVER CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. LIVER CANCER DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNO THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. CANADA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. CHINA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. INDIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. ITALY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. POLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. POLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. QATAR LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 101. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Liver Cancer Drugs Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Lion TCR Pte. Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information